Cadila Pharma Launches Rituximab And Teriparatide Biosimilars In India
Company Plans To Expand Its Biosimilars Portfolio
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.
You may also be interested in...
After launching bevacizumab, rituximab and teriparatide biosimilars in the last two months, Cadila Pharma has added to the portfolio with the launch of Cadalimab (adalimumab) in India.
Outlining plans to launch “multiple biosimilar products this year for the Indian market,” Cadila Pharmaceutical has just rolled out a biosimilar to Avastin (bevacizumab) in its domestic market.
Teva has completed its portfolio of digital inhalers by launching a further two products, AirDuo Digihaler (fluticasone propionate/salmeterol) and ArmonAir Digihaler (fluticasone propionate), in the US. The pair join the firm’s previously launched ProAir Digihaler (albuterol sulfate).